Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taspoglutide cardiovascular outcomes trial in type 2 diabetes with established cardiovascular disease
2009-014986-22Phase 3Terminated
- Sponsor
- Roche
- Start
- Oct 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Taspoglutide + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to first major cardiovascular event. Started Oct 2009; status: terminated.
02
Drugs
taspoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-014986-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014986-22.